



August 7, 2023

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

**Our subsidiary, Emendobio Inc., has been selected as the Best Startup of the Prix Galien USA Award, the Nobel Prize in the pharmaceutical field**

On July 27, 2023, our subsidiary EmendoBio Inc. (Emendo) was nominated for Best Startup in the 2023 Prix Galien USA Awards presented by the Galien Foundation.

David Baram, CEO of Emendo, commented."I am very excited that Emendo has been selected as a nominee for the prestigious Prix Galien Award for Best Startup. This is a good time to remind us all that Emendo is in the forefront of the scientific world of biotherapeutics."

The Prix Galien Award was created in 1969 by French pharmacologist Roland Merle to encourage advanced and outstanding pharmaceutical research and development. Named after the ancient physician Galen, the program began in 1970 for clinicians, pharmacologists, pharmacists, and pharmaceutical companies. Since the 1980s, academic experts in each country have been selecting and awarding prizes, and France, Germany, Belgium, the Netherlands, Luxembourg, Spain, Portugal, the United Kingdom, and the United States have established prizes named after their countries or regions.

Today, the Prix Galien Award is selected annually by more than 10 countries and regions, and is now even considered the Nobel Prize in the field of pharmaceuticals, and is awarded in the name of a country to those who have developed groundbreaking drugs.

The Prix Galien USA Award was launched in 2007 to recognize individuals who have impacted patient care, first through their unique medical products, later devices, and ultimately through innovation, but now Best Pharmaceutical Product, Best Biotechnology Product approved by the FDA in the past five years, In addition to Best Medical Technology, the awards are given for Best Digital Health Solution, Best Incubator/Accelerator/Equity, and Best Startup.

Prix Galien USA

<https://www.galienfoundation.org/prix-galien-usa>

(Note)This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.